



CELSR2 – rs646776




RYR2 – rs2819742




LIPC – rs1800588


Proportion of users on higher intensity dose



CETP – rs4783961




CETP – rs708272




CETP – rs1532624

Proportion of users on higher intensity dose




CYBA – rs4673



APOE – rs429358

Proportion of users on higher intensity dose



atorvastatin – ***

fluvastatin – ns

rosuvastatin – ns


simvastatin – ns

0/0

0/1 or 1/1


rs429358 allele

APOE – rs7412




- rs445925


Proportion of users on higher intensity dose




ADAMTS1 – rs428785




ADAMTS1 – rs402007




HMGCR – rs17671591



HMGCR – rs12654264




HMGCR – rs3846662




LPA – rs10455872

Proportion of users on higher intensity dose




- rs6924995




HLA-G – rs1063320

Proportion of users on higher intensity dose




TNF – rs1800629

Proportion of users on higher intensity dose




POR – rs1057868



LPL – rs328

Proportion of users on higher intensity dose



ABCA1 – rs2230806

Proportion of users on higher intensity dose

